Why did a promising heart drug fail? Doomed drug highlights complications of meddling with cholesterol. 1.The failure of a high-profile cholesterol drug has thrown a spotlight on the complicated machinery that regulates cholesterol levels. But many researchers remain confident that drugs to boost levels of good cholesterol are still one of the most promising means to combat spiralling heart disease. 2.Drug company Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib, a drug designed to raise heart-protective high-density lipoproteins (HDLs). In a trial of 15000 patients, a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone. 3.The news came as a kick in the teeth to many cardiologists because earlier tests in animals and people suggested it would lower rates of cardiovascular disease. There have been no red flags to my knowledge, says John Chapman, a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also studied torcetrapib. This cancellation came as a complete shock. 4.Torcetrapib is one of the most advanced of a new breed of drugs designed to raise levels of HDLs, which ferry cholesterol out of artery-clogging plaques to the liver for removal from the body. Specifically, torcetrapib blocks a protein called cholesterol ester transfer protein (CETP), which normally transfers the cholesterol from high-density lipoproteins to low density, plaque-promoting ones. Statins, in contrast, mainly work by lowering the bad low-density lipoproteins. Under pressure 5.Researchers are now trying to work out why and how the drug backfired, something that will not become clear until the clinical details are released by Pfizer. One hint lies in evidence from earlier trials that it slightly raises blood pressure in some patients. It was thought that this mild problem would be offset by the heart benefits of the drug. But it is possible that it actually proved fatal in some patients who already suffered high blood pressure. If blood pressure is the explanation, it would actually be good news for drug developers because it suggests that the problems are specific to this compound. Other prototype drugs that are being developed to block CETP work in a slightly different way and might not suffer the same downfall. 6.But it is also possible that the whole idea of blocking CETP is flawed, says Moti Kashyap, who directs atherosclerosis research at the VA Medical Center in Long Beach, California. When HDLs excrete cholesterol in the liver, they actually rely on LDLs for part of this process. So inhibiting CETP, which prevents the transfer of cholesterol from HDL to LDL, might actually cause an abnormal and irreversible accumulation of cholesterol in the body. Youre blocking a physiologic mechanism to eliminate cholesterol and effectively constipating the pathway, says Kashyap. Going up 7.Most researchers remain confident that elevating high density lipoproteins levels by one means or another is one of the best routes for helping heart disease patients. But HDLs are complex and not entirely understood. One approved drug, called niacin, is known to both raise HDL and reduce cardiovascular risk but also causes an unpleasant sensation of heat and tingling. Researchers are exploring whether they can bypass this side effect and whether niacin can lower disease risk more than statins alone. Scientists are also working on several other means to bump up high-density lipoproteins by, for example, introducing synthetic HDLs. The only thing we know is dead in the water is torcetrapib, not the whole idea of raising HDL, says Michael Miller, director of preventive cardiology at the University of Maryland Medical Center, Baltimore.
国内英语资讯:Xi meets Nepal Communist Party co-chairman to advance inter-party ties
Warm 温暖
国内英语资讯:Xi says China ready to advance friendly cooperation with Nepal
国内英语资讯:China, Pakistan vow to enhance pragmatic cooperation
蕾哈娜推出“最全”内衣产线,却被网友抨了
一周热词榜(5.12-18)
体坛英语资讯:Cavagna takes another dramatic stage in Vuelta de Espana
连续一周只吃健脑食品,会怎样?
国际博物馆日:盘点全球最奇特的八个博物馆
体坛英语资讯:Nowitzki appointed Chair of FIBA Players Commission for 2019-2023 term
国内英语资讯:Argentine vineyards ready to showcase top-tier wines at China import expo
国际英语资讯:Spotlight: Trump loses for 2nd time within week in legal fight to conceal financial records
再现神翻译 北京元大都公园西门被译成人名!
巴菲特最睿智的一句话
体坛英语资讯:Shanghais Kim leads S. Korea to rally past Dominica at womens VNL
国内英语资讯:Chinese NPC Tibetan delegation visits Switzerland, recounts development in Tibet
A Letter to Myself 给自己的一封信
体坛英语资讯:2-2 draw at Amiens denies Lyons chance to go Ligue 1 top
国内英语资讯:Senior official stresses eradicating poverty in west China on schedule
国际英语资讯:S. African court denies Zumas application for permanent stay of prosecution
国际英语资讯:Cuba confirms 110 dead in Fridays plane crash, 3 survivors in serious condition
研究表明 白葡萄酒会增加患前列腺癌的风险
国际英语资讯:Putin warns of threats from U.S. military buildup
卷福为女性发声!将男女平等贯彻到底
体坛英语资讯:World Urban Games follow initiative of Olympic Agenda 2020, says IOC President Bach
体坛英语资讯:Spain returns to FIBA World Cup final after 13 years
体坛英语资讯:Spain beat Argentina to claim first FIBA World Cup title since 2006
国际英语资讯:Spotlight: Environment for Chinese companies in EU satisfactory, but challenges remain: repo
能救命的健康小妙招
国内英语资讯:Xi, Modi meet to promote China-India mutual learning for shared prosperity
不限 |
英语教案 |
英语课件 |
英语试题 |
不限 |
不限 |
上册 |
下册 |
不限 |